253 related articles for article (PubMed ID: 22237958)
21. Multicenter, phase II study of gemcitabine and S-1 combination chemotherapy in patients with advanced biliary tract cancer.
Sasaki T; Isayama H; Nakai Y; Ito Y; Kogure H; Togawa O; Toda N; Yasuda I; Hasebe O; Maetani I; Sasahira N; Hirano K; Tsujino T; Tada M; Omata M
Cancer Chemother Pharmacol; 2010 May; 65(6):1101-7. PubMed ID: 19707761
[TBL] [Abstract][Full Text] [Related]
22. Phase II study of fixed dose-rate gemcitabine plus S-1 as a second-line treatment for advanced biliary tract cancer.
Kobayashi S; Ueno M; Sugimori K; Morizane C; Kojima Y; Irie K; Goda Y; Morimoto M; Ohkawa S
Cancer Chemother Pharmacol; 2017 Dec; 80(6):1189-1196. PubMed ID: 29071413
[TBL] [Abstract][Full Text] [Related]
23. Phase 1 study of Gemcitabine/Nab-paclitaxel/S-1 in patients with unresectable pancreatic cancer (GeNeS1S trial).
Sai S; Toyoda M; Tobimatsu K; Satake H; Yasui H; Kimbara S; Koyama T; Fujishima Y; Imamura Y; Funakoshi Y; Kiyota N; Toyama H; Kodama Y; Minami H
Cancer Chemother Pharmacol; 2021 Jan; 87(1):65-71. PubMed ID: 33098471
[TBL] [Abstract][Full Text] [Related]
24. A phase I study for adjuvant chemotherapy of gemcitabine plus S-1 in curatively resected patients with biliary tract cancer: adjusting the dose of adjuvant chemotherapy according to the surgical procedures.
Takahara T; Nitta H; Hasegawa Y; Itou N; Takahashi M; Nishizuka S; Wakabayashi G
Cancer Chemother Pharmacol; 2012 May; 69(5):1127-33. PubMed ID: 22207029
[TBL] [Abstract][Full Text] [Related]
25. Randomized phase II study of gemcitabine plus S-1 versus S-1 in advanced biliary tract cancer: a Japan Clinical Oncology Group trial (JCOG 0805).
Morizane C; Okusaka T; Mizusawa J; Takashima A; Ueno M; Ikeda M; Hamamoto Y; Ishii H; Boku N; Furuse J
Cancer Sci; 2013 Sep; 104(9):1211-6. PubMed ID: 23763511
[TBL] [Abstract][Full Text] [Related]
26. A phase I study of combination chemotherapy with gemcitabine and oral S-1 for advanced pancreatic cancer.
Ueno H; Okusaka T; Ikeda M; Ishiguro Y; Morizane C; Matsubara J; Furuse J; Ishii H; Nagase M; Nakachi K
Oncology; 2005; 69(5):421-7. PubMed ID: 16319514
[TBL] [Abstract][Full Text] [Related]
27. Performance of outpatient regimen of S-1 in combination with fractional cisplatin for advanced or recurrent gastric cancers: a phase I study.
Shimoyama S; Imamura K; Hiki N; Yamaguchi H; Mafune K; Kaminishi M
Int J Clin Oncol; 2005 Aug; 10(4):251-5. PubMed ID: 16136370
[TBL] [Abstract][Full Text] [Related]
28. Phase I trial of oral S-1 plus gemcitabine in elderly patients with nonsmall cell lung cancer.
Kaira K; Sunaga N; Yanagitani N; Aoki H; Kawata T; Utsugi M; Shimizu Y; Shimizu K; Hisada T; Ishizuka T; Mori M
Anticancer Drugs; 2008 Mar; 19(3):289-94. PubMed ID: 18510175
[TBL] [Abstract][Full Text] [Related]
29. Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial.
Valle JW; Wasan H; Lopes A; Backen AC; Palmer DH; Morris K; Duggan M; Cunningham D; Anthoney DA; Corrie P; Madhusudan S; Maraveyas A; Ross PJ; Waters JS; Steward WP; Rees C; Beare S; Dive C; Bridgewater JA
Lancet Oncol; 2015 Aug; 16(8):967-78. PubMed ID: 26179201
[TBL] [Abstract][Full Text] [Related]
30. Initial safety and efficacy of cisplatin and gemcitabine combination chemotherapy for unresectable biliary tract cancer.
Shibata Y
Gan To Kagaku Ryoho; 2014 Dec; 41(13):2599-602. PubMed ID: 25596055
[TBL] [Abstract][Full Text] [Related]
31. Phase I/II trial of combination therapy with S-1 and weekly paclitaxel in patients with unresectable or recurrent gastric cancer.
Inada S; Tomidokoro T; Fukunari H; Sato T; Hatano T; Nishimura A; Kawauchi Y; Nikkuni K; Shimizu T; Sato T; Yanagi M; Takahashi S; Yoshida H; Sugita M; Hayashi T
Cancer Chemother Pharmacol; 2009 Jan; 63(2):267-73. PubMed ID: 18379784
[TBL] [Abstract][Full Text] [Related]
32. Adjuvant treatment of resectable biliary tract cancer with cisplatin plus gemcitabine: A prospective single center phase II study.
Siebenhüner AR; Seifert H; Bachmann H; Seifert B; Winder T; Feilchenfeldt J; Breitenstein S; Clavien PA; Stupp R; Knuth A; Pestalozzi B; Samaras P
BMC Cancer; 2018 Jan; 18(1):72. PubMed ID: 29325521
[TBL] [Abstract][Full Text] [Related]
33. A phase I safety, pharmacological, and biological study of the farnesyl protein transferase inhibitor, lonafarnib (SCH 663366), in combination with cisplatin and gemcitabine in patients with advanced solid tumors.
Chow LQ; Eckhardt SG; O'Bryant CL; Schultz MK; Morrow M; Grolnic S; Basche M; Gore L
Cancer Chemother Pharmacol; 2008 Sep; 62(4):631-46. PubMed ID: 18058098
[TBL] [Abstract][Full Text] [Related]
34. Liposomal irinotecan plus fluorouracil and leucovorin versus fluorouracil and leucovorin for metastatic biliary tract cancer after progression on gemcitabine plus cisplatin (NIFTY): a multicentre, open-label, randomised, phase 2b study.
Yoo C; Kim KP; Jeong JH; Kim I; Kang MJ; Cheon J; Kang BW; Ryu H; Lee JS; Kim KW; Abou-Alfa GK; Ryoo BY
Lancet Oncol; 2021 Nov; 22(11):1560-1572. PubMed ID: 34656226
[TBL] [Abstract][Full Text] [Related]
35. Capecitabine combined with gemcitabine (CapGem) as first-line treatment in patients with advanced/metastatic biliary tract carcinoma.
Cho JY; Paik YH; Chang YS; Lee SJ; Lee DK; Song SY; Chung JB; Park MS; Yu JS; Yoon DS
Cancer; 2005 Dec; 104(12):2753-8. PubMed ID: 16294346
[TBL] [Abstract][Full Text] [Related]
36. Randomized Phase III study of gemcitabine plus S-1 versus gemcitabine plus cisplatin in advanced biliary tract cancer: Japan Clinical Oncology Group Study (JCOG1113, FUGA-BT).
Mizusawa J; Morizane C; Okusaka T; Katayama H; Ishii H; Fukuda H; Furuse J;
Jpn J Clin Oncol; 2016 Apr; 46(4):385-8. PubMed ID: 27025903
[TBL] [Abstract][Full Text] [Related]
37. Phase I/II study of 3-week combination of S-1 and cisplatin chemotherapy for metastatic or recurrent gastric cancer.
Lee JL; Kang HJ; Kang YK; Ryu MH; Chang HM; Kim TW; Sohn HJ; Kim H; Lee JS
Cancer Chemother Pharmacol; 2008 Apr; 61(5):837-45. PubMed ID: 17579864
[TBL] [Abstract][Full Text] [Related]
38. Phase I study of oral S-1 plus Cisplatin with concurrent radiotherapy for locally advanced non-small-cell lung cancer.
Kaira K; Sunaga N; Yanagitani N; Kawata T; Utsugi M; Shimizu K; Ebara T; Kawamura H; Nonaka T; Ishikawa H; Sakurai H; Suga T; Hara K; Hisada T; Ishizuka T; Nakano T; Mori M
Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):109-14. PubMed ID: 18929446
[TBL] [Abstract][Full Text] [Related]
39. A Phase II study of gemcitabine and cisplatin in advanced biliary tract cancer.
Kim ST; Park JO; Lee J; Lee KT; Lee JK; Choi SH; Heo JS; Park YS; Kang WK; Park K
Cancer; 2006 Mar; 106(6):1339-46. PubMed ID: 16475213
[TBL] [Abstract][Full Text] [Related]
40. A phase I study of triplet combination chemotherapy of paclitaxel, cisplatin and S-1 in patients with advanced gastric cancer.
Kimura Y; Yano H; Imamura H; Fujitani K; Imano M; Tokunaga Y; Matsuoka M; Kurokawa Y; Shimokawa T; Takiuchi H; Tsujinaka T; Furukawa H
Jpn J Clin Oncol; 2013 Feb; 43(2):125-31. PubMed ID: 23225911
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]